Effect of Cabergoline Treatment on Cushing's Disease Caused by Pituitary Macroadenoma after Incomplete Transsphenoidal Surgery.
- Author:
Eun Jung YOO
1
;
Eun Soo YOO
;
Young Geon KIM
;
Yong Jun CHOI
;
Seung Jin HAN
;
Yoon Sok CHUNG
Author Information
1. Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea. yschung@ajou.ac.kr
- Publication Type:Case Report
- Keywords:
Adrenocorticotropic hormone;
Cushing syndrome;
Pituitary neoplasms;
Cabergoline
- MeSH:
ACTH-Secreting Pituitary Adenoma;
Adenoma;
Adrenocorticotropic Hormone;
Cushing Syndrome;
Dexamethasone;
Female;
Humans;
Hydrocortisone;
Immunohistochemistry;
Magnetic Resonance Imaging;
Middle Aged;
Obesity, Abdominal;
Pituitary Neoplasms;
Plasma
- From:Soonchunhyang Medical Science
2015;21(2):227-231
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The present case involves a 56-year-old woman with Cushing's disease due to pituitary macroadenoma. The patient had suffered from central obesity, general weakness for 1 year. Her serum cortisol levels were elevated throughout the observation period and the dexamethasone test failed to suppress the cortisol secretion. Plasma adrenocorticotropic hormone (ACTH) levels were significantly elevated (386 pg/mL). Sellar magnetic resonance imaging revealed a 3.1-cm pituitary tumor occupying the sellar region with extension to parasellar area. The pituitary mass was removed by transsphenoidal surgery incompletely and was pathologically identified as compatible to ACTH-producing pituitary adenoma by immunohistochemistry. Thereafter, cabergoline (1 mg/wk) was administered for the remnant adenoma, which gradually reduced ACTH levels in 7 days before starting radiation therapy. This case demonstrates the efficacy of cabergoline to treat Cushing's disease caused by pituitary macroadenoma.
